Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|October 25, 2006
Respiratory sufferers breathing easier
Increased treatment using combination therapies
Advertisement
Sufferers of respiratory diseases, such as asthma and chronic pulmonary disease (COPD), are breathing easier as a result of increased treatments using fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. The appeal of these combinations is three-fold: improved patient compliance, simplified disease management, and the certainty of bronchodilator and steroid co-administration.
Previously, only two such combination inhalers were available; GSK's Advair/Seretide (fluticasone/salmeterol) and AstraZeneca's Symbicort (budesonide/formoterol). With sales reaching over $4.9 billion in 2005, Advair/Seretide dominates not only its field, but also the total asthma/COPD market. However, a report by Datamonitor, an independent market analyst company, states that Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, suggest a major change in the market dynamics.
www.datamonitor.com
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement